Currently, TRIM31 and TRIM8 are considered highly promising therapeutic targets, and researchers have embarked on drug-targeting studies against TRIM31 and TRIM8 to explore their application in NAFLD therapy. Here, TRIM31 is linked to metabolic dysfunction-associated steatotic liver disease.